Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
AssigneeOmeros Corporation
InventorsJohn Benjamin Leppard, Christi L. Wood, W. Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S. Allison, Larry W. Tjoelker
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
Claims23
A method for treating a patient having a cancer associated with FN14 expression, comprising administering to the patient a composition comprising a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to human FN14, wherein the antibody or fragment thereof comprises a heavy chain variable region comprising a VHCDR1 amino acid sequence, a VHCDR2 amino acid sequence and a VHCDR3 amino acid sequence set forth in SEQ ID NO:93, wherein Xaa at position 2 is Ala or Gly, Xaa at position 4 is Ser or Thr, and Xaa at position 5 is Ser or Gly;
- thereby treating the cancer associated with FN14 expression.
A method for preventing or reducing the likelihood of occurrence of metastasis of a cancer associated with FN14 expression, comprising administering to a patient suffering with a cancer associated with FN14 expression a composition comprising a therapeutically effective amount of an antibody, or antigen-binding fragment thereof, that binds to human FN14, wherein the antibody or fragment thereof comprises a heavy chain variable region comprising a VHCDR1 amino acid sequence, a VHCDR2 amino acid sequence and a VHCDR3 amino acid sequence set forth in SEQ ID NO:93, wherein Xaa at position 2 is Ala or Gly, Xaa at position 4 is Ser or Thr, and Xaa at position 5 is Ser or Gly;
- and thereby preventing or reducing the likelihood of occurrence of a metastasis of the cancer associated with FN14 expression.
Dependencies are inferred from the claim text.